| Literature DB >> 33708882 |
Ziquan Li1,2, Cong Zhang3, Bintao Qiu4, Yuchen Niu4, Ling Leng4, Siyi Cai1,5, Ye Tian1, Terry Jianguo Zhang1,2,5, Guixing Qiu1,2,5, Nan Wu1,2,5, Zhihong Wu2,4,5, Yipeng Wang1,2,5.
Abstract
BACKGROUND: Klippel-Feil syndrome (KFS) represents the rare and complex deformity characterized by congenital defects in the formation or segmentation of the cervical vertebrae. There is a wide gap in understanding the detailed mechanisms of KFS because of its rarity, heterogeneity, small pedigrees, and the broad spectrum of anomalies.Entities:
Keywords: FXR/RXR activation; Klippel-Feil syndrome (KFS); LXR/RXR activation; congenital scoliosis (CS); differentially abundant proteins (DAPs); lipid metabolism
Year: 2021 PMID: 33708882 PMCID: PMC7940892 DOI: 10.21037/atm-20-5155
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Figure 1Flowchart of the study design.
Figure 2Visualization and functional analysis of differentially abundant proteins (DAPs) in patients with Klippel-Feil syndrome (KFS) compared with healthy controls. (A) Volcano plot showing the 49 significant DAPs; 22 were increased and 27 were decreased. All the identified proteins (493) are plotted on the x-axis; the P values are plotted on the y-axis. Green, red, and gray dots indicate proteins with decreased, increased, and no change in abundance, respectively. (B) Protein-protein interaction network of the 49 DAPs. Solid lines indicate direct molecular interactions that have experimental confirmation; dashed lines indicate indirect interactions. Nodes in green and red indicate proteins with decreased and increased abundance, respectively. Uncolored nodes indicate potential target proteins that are functionally related to the DAPs. (C) Gene ontology (GO) functional annotation of the DAPs under the biological process (BP), molecular function (MF), and cellular component (CC) categories.
Figure 3Visualization and functional analysis of differentially abundant proteins (DAPs) in patients with Klippel-Feil syndrome (KFS) compared with patients with congenital scoliosis (CS). (A) Volcano plot showing the 192 significant DAPs; 74 were increased and 118 were decreased. All the identified proteins (462) are plotted on the x-axis; the P-values are plotted on the y-axis. Green, red, and gray dots indicate proteins with decreased, increased, and no change in abundance, respectively. (B) The most significant protein-protein interaction network of the 192 DAPs. Solid lines indicate direct molecular interactions that have experimental confirmation; dashed lines indicate indirect interactions. Nodes in green and red indicate proteins with decreased and increased abundance, respectively. Uncolored nodes indicate potential target proteins that are functionally related to the DAPs. (C) Gene ontology (GO) functional annotation of the DAPs under the biological process, molecular function, and cellular component categories.
Differentially expressed proteins involved in both comparisons (KFS patients compared with control participants and CS patients)
| Swiss-Prot accession no. | Swiss-Prot entry name | Protein Name | KFS patients/CS patients | KFS patients/control participants | |||||
|---|---|---|---|---|---|---|---|---|---|
| P value | Fold change | Regulation | P value | Fold change | Regulation | ||||
| P01834 | IGKC_HUMAN | Immunoglobulin kappa constant | 0.00039 | 3.73427 | Up | 0.01193 | 0.43808 | Down | |
| B9A064 | IGLL5_HUMAN | Immunoglobulin lambda-like polypeptide 5 | 0.00012 | 2.46926 | Up | 0.02048 | 0.47431 | Down | |
| P0DOY2 | IGLC2_HUMAN | Immunoglobulin lambda constant 2 | 0.00163 | 1.90980 | Up | 0.01578 | 0.47591 | Down | |
| A0A2Q2TTZ9 | A0A2Q2TTZ9_HUMAN | Immunoglobulin kappa variable 1-33 | 0.00045 | 2.26433 | Up | 0.02794 | 0.43106 | Down | |
| P01857 | IGHG1_HUMAN | Immunoglobulin heavy constant gamma 1 | 0.00015 | 3.06671 | Up | 0.03517 | 0.51085 | Down | |
| P01860 | IGHG3_HUMAN | Immunoglobulin heavy constant gamma 3 | 0.00040 | 2.65677 | Up | 0.04317 | 0.51696 | Down | |
| P01599 | KV117_HUMAN | Immunoglobulin kappa variable 1-17 | 0.03687 | 1.53585 | Up | 0.01533 | 0.50120 | Down | |
| P01718 | LV327_HUMAN | Immunoglobulin lambda variable 3-27 | 0.04720 | 1.62870 | Up | 0.03967 | 0.49733 | Down | |
| Q06830 | PRDX1_HUMAN | Peroxiredoxin-1 | 0.00115 | 0.24445 | Down | 0.01905 | 0.50629 | Down | |
| P04406 | G3P_HUMAN | Glyceraldehyde-3-phosphate dehydrogenase | 0.00073 | 0.41659 | Down | 0.00670 | 1.58071 | Up | |
| P33151 | CADH5_HUMAN | Cadherin-5 | 0.01285 | 0.69025 | Down | 0.00159 | 1.81037 | Up | |
| Q6YHK3 | CD109_HUMAN | CD109 antigen | 0.02784 | 1.74779 | Up | 0.00721 | 1.81076 | Up | |
| Q08380 | LG3BP_HUMAN | Galectin-3-binding protein | 0.00705 | 2.77056 | Up | 0.00668 | 2.08792 | Up | |
| Q16853 | AOC3_HUMAN | Membrane primary amine oxidase | 0.00638 | 1.58299 | Up | 0.00141 | 1.66984 | Up | |
| Q99784 | NOE1_HUMAN | Noelin | 0.00085 | 2.05215 | Up | 0.00488 | 1.62694 | Up | |
KFS, Klippel-Feil syndrome; CS, congenital scoliosis.
Figure 4Cluster analyses of differentially abundant proteins (DAPs) that were common in the patients with Klippel-Feil syndrome (KFS) vs. healthy controls and patients with KFS vs. patients with congenital scoliosis (CS) comparisons. The abundance levels of the 15 candidate DAPs in patients with KFS, patients with CS, and healthy controls are shown. Rows represent individual proteins; columns indicate individual participants. Blue indicates decreased protein abundance; red indicates increased protein abundance.
Figure 5Top ten canonical pathways that were common in the patients with Klippel-Feil syndrome (KFS) vs. healthy controls and patients with KFS vs. patients with congenital scoliosis (CS) comparisons. Differentially abundant proteins (DAPs) from the two comparisons were imported to the IPA software. The cellular signaling pathway histogram depicts the most relevant canonical pathways ranked by −log (P value). The LXR/RXR and FXR/RXR activation pathways were identified as common significant canonical pathways in both comparisons.
Differentially expressed proteins involved in LXR/RXR activation and FXR/RXR activation pathways
| Swiss-Prot accession no. | Swiss-Prot entry name | Protein name | P value | Fold change |
|---|---|---|---|---|
| P05090 | APOD_HUMAN | Apolipoprotein D | 0.00576 | 3.589 (KFS/CS) |
| Q15166 | PON3_HUMAN | Serum paraoxonase/lactonase 3 | 0.00097 | 2.493 (KFS/CS) |
| P02787 | TRFE_HUMAN | Serotransferrin | 0.04135 | 2.156 (KFS/CS) |
| P27169 | PON1_HUMAN | Serum paraoxonase/arylesterase 1 | 0.00397 | 2.074 (KFS/CS) |
| P02765 | FETUA_HUMAN | Alpha-2-HS-glycoprotein | 0.00965 | 1.895 (KFS/CS) |
| P43652 | AFAM_HUMAN | Afamin | 0.02521 | 1.853 (KFS/CS) |
| Q9NPH3 | IL1AP_HUMAN | Interleukin-1 receptor accessory protein | 0.00938 | 1.488 (KFS/CS) |
| P02753 | RET4_HUMAN | Retinol-binding protein 4 | 0.04721 | 0.684 (KFS/CS) |
| P02649 | APOE_HUMAN | Apolipoprotein E | 0.01181 | 0.671 (KFS/CS) |
| P02774 | VTDB_HUMAN | Vitamin D-binding protein | 0.00167 | 0.647 (KFS/CS) |
| P02652 | APOA2_HUMAN | Apolipoprotein A-II | 0.02753 | 0.605 (KFS/CS) |
| Q9UHG3 | PCYOX_HUMAN | Prenylcysteine oxidase 1 | 0.00885 | 0.525 (KFS/CS) |
| P02671 | FIBA_HUMAN | Fibrinogen alpha chain | 0.00167 | 0.422 (KFS/CS) |
| P02749 | APOH_HUMAN | Beta-2-glycoprotein 1 | 3.44E-07 | 0.414 (KFS/CS) |
| Q14624 | ITIH4_HUMAN | Inter-alpha-trypsin inhibitor heavy chain H4 | 0.02197 | 0.412 (KFS/CS) |
| P08571 | CD14_HUMAN | Monocyte differentiation antigen CD14 | 0.00220 | 0.321 (KFS/CS) |
| P01009 | A1AT_HUMAN | Alpha-1-antitrypsin | 0.00080 | 0.265 (KFS/CS) |
| P0DJI8 | SAA1_HUMAN | Serum amyloid A-1 protein | 0.00575 | 0.168 (KFS/CS) |
| P0DJI9 | SAA2_HUMAN | Serum amyloid A-2 protein | 0.01124 | 0.168 (KFS/CS) |
| P06727 | APOA4_HUMAN | Apolipoprotein A-IV | 0.01882 | 2.450 (KFS/Control) |
| P02656 | APOC3_HUMAN | Apolipoprotein C-III | 0.00670 | 1.795 (KFS/Control) |
| Q13790 | APOF_HUMAN | Apolipoprotein F | 0.04506 | 1.663 (KFS/Control) |
| P04004 | VTNC_HUMAN | Vitronectin | 0.04533 | 1.576 (KFS/Control) |
KFS, Klippel-Feil syndrome; CS, congenital scoliosis.